Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
Date:5/17/2010

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

Cambridge, Mass. (PRWEB) May 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

“Our team is quite excited to test this combination in clinical trials given the preclinical data we have produced showing that MM-111 and Herceptin® have very complementary mechanisms of action,” said Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack. “We believe that by combining the two candidates, we have the potential to treat a number of HER2 positive breast cancer patients who are not benefiting from current treatments.”

The Phase 1 /2 study will initially evaluate the human safety and pharmacokinetics of MM-111 in combination with Herceptin® and establish a safe regimen. The Phase 2 portion of the study will then investigate the regimen’s efficacy in the advanced Her2 positive breast cancer patient population. The trial is based on preclinical work showing that MM-111 and Herceptin® positively combine to inhibit the growth of ErbB2 over-expressing breast cancer cells. The Gabrail Cancer Center in Canton, Ohio, Huntsman Cancer Institute in Salt Lake City, Utah, and the Massachusetts General Hospital in Boston, Massachusetts, will part
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
4. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, ... its three Promissory Note holders, two of whom are ... in July 2014 for a total of $ 300,000 ... into 3,500,001 restricted common shares. Notes were repayable within ... and the coupon were convertible into common shares to ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... On Wednesday, October,22, 2008, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
... BOCA RATON, Fla., Sept. 8 NovaVision today ... at the prestigious AdvaMed,2008: The MedTech Conference ... DC., During the presentation, which falls in ... appointed chief executive officer of,NovaVision, will address the ...
... 8 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... 2008 Small Cap Healthcare Conference will be webcast and,may ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ), A member of Human Genome ... Wednesday, September 10, 2008 at 10:15 am Eastern,Time., ...
Cached Biology Technology:NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... People who suffer from asthma may think there,s not ... besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the scientific ... Immunology (ACAAI), asthma sufferers can learn lessons about managing ... in the Annals article improved her asthma once she ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... the publication of several commentaries in the scientific journal ... embryos it is safe and proper to place in a uterus, ... faced by all patients anxiously caught between no pregnancies at all ... place it is often all too easy to think that the ...
... German . The Deutsche Forschungsgemeinschaft (DFG, German ... Research Units and two Humanities Centres for Advanced Studies. This ... its July meeting in Bonn. The aim of the research ... devote their time to current and urgent questions in their ...
... Reserve University School of Medicine has received a $2.1 million ... the National Institutes of Health (NIH), to expand basic research ... is an inherited disease that causes thick, sticky mucus to ... NIH grant was awarded to Mitchell Drumm, PhD, and Craig ...
Cached Biology News:IVF treatment and multiple births: Free-market patient rights versus government regulation 2IVF treatment and multiple births: Free-market patient rights versus government regulation 3From bone metastases to water supply 2From bone metastases to water supply 3From bone metastases to water supply 4From bone metastases to water supply 5From bone metastases to water supply 6CWRU receives $2.1 million NIH grant to expand cystic fibrosis research models 2
EML1 (K-16)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
Biology Products: